**Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)** This study aims to learn more about the medication *hydroxyurea* for treating *sickle cell anemia* (SCA). Sickle cell anemia is a blood disorder where red blood cells are shaped like a sickle and can block blood flow. Hydroxyurea is a medicine that helps people with SCA feel better. This study wants to find new ways to decide the right dose of hydroxyurea for each person and to understand its long-term effects. Usually, the dose is based on weight, but this study will look at how each patient's body absorbs the medicine. **Key Points:** - The study will look at how hydroxyurea affects different parts of the body like the brain, heart, and kidneys. - Children with sickle cell anemia as young as 6 months can join if they are not receiving regular blood transfusions. - The study involves new ways to start and adjust the hydroxyurea dosage for the best results. **

Eligibility: Kids diagnosed with sickle cell anemia, ages 6 months and older, can participate.

**